1217667-10-1

(–)-Ropivacaine-d₇ is intended for use as an internal standard for the quantification of (–)-ropivacaine by GC- or LC-MS. (–)-Ropivacaine is a potent and reversible blocker of sodium channels in nerve fibers. In vivo, (–)-ropivacaine induces complete impairment of proprioception, motor function, and nociception in the hindleg of rats when 100 μL of an 8 mM solution is injected percutaneously into the sciatic nerve. (–)-Ropivacaine depresses myocardial contractile force in isolated rat hearts less potently than (±)-ropivacaine, as well as (–)- and (±)-bupivacaine . Formulations containing (–)-ropivacaine have been used as local anesthetics during surgery and childbirth.

White Solid

Labelled Ropivacaine (R675000). Anesthetic (local).

[1] HANSEN T G. Ropivacaine: a pharmacological review.[J]. Expert Review of Neurotherapeutics, 2004, 4 5: 781-791. DOI: 10.1586/14737175.4.5.781
[2] CATHERINE J SINNOTT B.A.  Gary R S Ph D. Levobupivacaine versus ropivacaine for sciatic nerve block in the rat[J]. Regional Anesthesia and Pain Medicine, 2003, 28 4: Pages 294-303. DOI: 10.1016/s1098-7339(03)00188-3
[3] MATHEUS FéCCHIO PINOTTI. Myocardial contractility impairment with racemic bupivacaine, non-racemic bupivacaine and ropivacaine. A comparative study.[J]. Acta cirurgica brasileira, 2015, 30 7: 484-490. DOI: 10.1590/s0102-865020150070000006